Últimas noticias sobre Imunon (NASDAQ:IMNN) Bolsa

IMUNON INC

Imunon

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Box,Headquarters,In,Redwood,City,,California,,Usa,-,June,8,

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BROG

CETX

CODI

GLXY

IFRX

IMNN

JFBR

JOBY

LAES

LVWR

NEHC

OKTA

PMAX

SGBX

SONN

WORX

Descubre qué acciones destacan en el premercado de EE. UU., desde subidas explosivas como Box hasta caídas por anuncios clave.

Las acciones de Box se disparan un 12%; Aquí están 20 acciones que se mueven en el premercado

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IXHL

ONCY

PRTA

SBET

SILO

VVPR

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

Imunon Inc

Macro Economic Events

Politics

Global

Economics

General

Reuters Citing A German Diplomatic Source Says Foreign Ministers Of Germany, France, Britain And Top EU Diplomat To Hold Nuclear Talks With Iranian Counterpart On Friday In Geneva

Reuters Cites Court Filing Saying Families Of Boeing 737 Max Victims Ask Judge Not To Dismiss Criminal Case Against Planemaker

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tafasitamab-cxix-relapsed-or-refractory-follicular-lymphoma</a>

INCY

'FDA Approves Tafasitamab-cxix For Relapsed Or Refractory Follicular Lymphoma' - FDA

JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) shares are trading higher Wednesday afternoon. The stock is gaining following a <a href="https://www.bloomberg.com/news/articles/2025-06-18/us-plans-to-ease-capital-rule-limiting-banks-treasury-trades?embedded-checkout=true">report</a> from Bloomberg that top U.S. regulators are planning to significantly reduce capital requirements for the nation&#8217;s largest banks.
What To Know: According to Bloomberg, the Federal Reserve, FDIC and OCC are set to lower the enhanced supplementary leverage ratio, a key capital buffer. The proposal would decrease the required capital from 5% to a range of 3.5% to 4.5% for bank holding companies like JPMorgan.
This easing of regulations, which Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-06-18/us-plans-to-ease-capital-rule-limiting-banks-treasury-trades?embedded-checkout=true">reports</a> will be discussed at a Federal Reserve meeting on June 25, is seen as a major victory for Wall Street. The move is expected to free up substantial capital for JPMorgan Chase.
Read Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/46004338/no-rate-cuts-yet-fed-flags-slower-growth-sticky-inflation">No Rate Cuts Yet: Fed Flags Slower Growth, Sticky Inflation</a>
Analysts suggest this could lead to increased share buybacks, higher dividends for investors and expanded capacity for profitable trading in the crucial U.S. Treasuries market.
Furthermore, the reduced capital burden could empower JPMorgan to expand its lending activities to both corporate and consumer clients, driving core revenue growth. The regulatory relief may also enhance the bank&#8217;s competitive standing against large European and Asian rivals who operate under different capital frameworks.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JPMorgan shares are up 1.72% to $274.13 Wednesday afternoon. The stock has a 52-week high of $280.25 and a low of $190.90.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46004089/gamestop-stock-is-rising-wednesday-whats-going-on">GameStop Stock Is Rising Wednesday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy JPM Stock</h2>
By now you're likely curious about how to participate in the market for JPMorgan Chase &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of JPMorgan Chase, which is trading at $274.13 as of publishing time, $100 would buy you 0.36 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

What's Going On With JPMorgan Chase (JPM) Stock?

JPMorgan analyst Matthew R. Boss has updated quarterly models for <a href="https://www.benzinga.com/topic/retail">some department store companies</a>.
Here are his views on three retailers.
<h3 class="wp-block-heading">Kohl&#8217;s</h3>
Despite sales gains tied to in-store efforts like Sephora and Home Décor, Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) continues to face revenue declines in several segments—apparel, footwear, and legacy homes.
The analyst also flagged structural risks to Kohl's store footprint, which makes up over half of U.S. department stores. Adjusted debt/EBITDAR ended 2023 at 3.6x—that&#8217;s well above the company's ~2.5x target. Continued same-store sales pressure and margin erosion is likely pushing leverage above 4x through 2024–26, based on JPMorgan estimates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45891695/bofa-securities-warns-tariffs-could-still-weigh-on-retail-stocks-such-as-gap-ralph-lauren" rel="noreferrer noopener">BofA Securities Warns Tariffs Could Still Weigh On Retail Stocks Such As Gap, Ralph Lauren</a>
Boss forecasts fiscal year 2025 EPS of 56 cents and fiscal year 2026 EPS of 53 cents, both above Street estimates of 41 cents and 47 cents, respectively.
The analyst maintains an Underweight rating on the stock with a price forecast of $8, unchanged.
<h3 class="wp-block-heading">Vail Resorts</h3>
Boss writes that Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) may be approaching a turning point in revenue and earnings as FY25 winds down, helped by the return of former CEO Katz and unique growth drivers.
The analyst highlights the company&#8217;s premium resort portfolio, upfront revenue via its Epic Pass strategy, and a more resilient customer base of high-income, frequent skiers as key advantages.
Boss projects fiscal year 2025 adjusted EBITDA at $866 million and fiscal year 2026 at $908 million, both slightly above Street estimates.
The analyst keeps a Neutral rating on Vail Resorts, with a price forecast of $167.
<h3 class="wp-block-heading">Foot Locker</h3>
Boss notes that while Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) has faced challenges from inconsistent same-store sales, increased promotions, and brand allocation changes—particularly with Nike, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)—Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) aims to revamp the business through its $2.4 billion acquisition.
The deal is intended to create a larger global retail sports platform, strengthen brand partnerships, enhance omni-channel capabilities, and unlock synergies.
Boss models fiscal year 2025 EPS for Foot Locker at $1.10, ahead of the Street's $1.00, and projects fiscal year 2026 EPS to rise to $1.65.
The analyst reiterated the Neutral rating on the stock, with a price forecast of $24.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46004338/no-rate-cuts-yet-fed-flags-slower-growth-sticky-inflation" target="_blank" rel="noreferrer noopener">No Rate Cuts Yet: Fed Flags Slower Growth, Sticky Inflation</a></li>
</ul>
Image: Shutterstock

Equities

Analyst Ratings

Retail Reality Check: JPMorgan Flags Kohl's Leverage Risks, Sees Signs of Stability At Vail And Foot Locker

BLNE

Beeline Holdings Shares Halted On Circuit Breaker To The Downside, Stock Now Up 27.4%

Shares of TruGolf Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) are trading lower Wednesday after the company announced a 1-for-50 reverse stock split set to<a href="https://www.benzinga.com/pressreleases/25/06/g45992818/trugolf-announces-reverse-stock-split"> take effect on June 23, 2025. </a>
What To Know: The reverse stock split will consolidate every fifty shares of TruGolf's Class A common stock into one share. The company's outstanding share count will fall from approximately 40.5 million to around 0.8 million. The number of authorized shares, however, remains unchanged at 650 million. 
Reverse splits can be viewed negatively by investors, especially when used to help a stock remain compliant with minimum price requirements for Nasdaq listing.
Is TRUG A Good Stock To Buy?
TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 20.65%, you'll need to buy a share of North American Finl 15 by the Jun. 30, 2025. Once done, you can expect to receive a nominal payout of $0.11 on Jul. 10, 2025.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/TRUG">TruGolf Holdings</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
TRUG Price Action: TrueGolf Shares were down 21.9% at 13 cents at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45999380/trump-powell-again-markets-breathe-iran-rejects-demands">Trump Slams Powell Again, Yet Markets Breathe As Iran Rejects President&#8217;s Demands</a></li>
</ul>
Image Created With Artificial Intelligence.

TRUG

TruGolf Shares Sink Following 1-for-50 Reverse Stock Split Announcement

<a href="https://www.youtube.com/watch?v=BpbgACcMHFk">https://www.youtube.com/watch?v=BpbgACcMHFk</a>

iShares MSCI Israel Capped Investable Market Index Fund

President Trump Says Haven't Closed Door On Meeting Iran; Says My Supporters Don't Want To See Iran Get A Nuclear Weapon

Beeline Holdings Shares Resume Trade

President Trump On Acting Against Fordow Says Haven't Made A Decision

Beeline Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 46.8%

Beeline Holdings, Inc. ("Beeline") is furnishing this report to announce today that it has closed its first fractional equity sale leveraging a stablecoin-based transaction structure.
&nbsp;
This marks the initial transaction in a series of five to 10 similar "beta" transactions currently scheduled to be executed over the coming weeks, ahead of a planned national launch expected to begin in early August 2025. These transactions are not dependent upon current or future prevailing interest rates unlike a typical home mortgage.
&nbsp;
Beeline previously furnished information on this transaction structure in Current Reports on Form 8-K filed on June 4, 2025 and June 9, 2025. Beeline intends to disclose further details as more transactions close.
&nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Beeline Holdings Closes First Fractional Equity Sale Using Stablecoin-Based Structure, Kicking Off Series of Beta Transactions Ahead Of August 2025 National Launch

<a href="https://www.youtube.com/watch?v=aLI1V4kKFME">https://www.youtube.com/watch?v=aLI1V4kKFME</a>
&nbsp;

Federal Reserve

Fed Chair Powell Says U.S. Economy Has Defied All Kinds Of Forecasts For It To Weaken; Policymakers Do Not Have A High Conviction About Rate Path; A Rate Hike Is Not Base Case

President Trump Says Think Iran Was A Few Weeks Away From Having A Nuclear Weapon

President Trump Says Discussed Iran With Pakistani Army Official; Says Israel Doing Pretty Well

Fed Chair Powell Says Don't See Increased Slack In Labor Market, Except At The Margin; 4.2% Is At Low-End Of Estimates Of Sustainable Long-Run Unemployment Rate

President Trump Says Meeting In An Hour On Iran-israel; Iran Wants To Meet, 'may Do That'; Says Have Not Made A Final Decision Yet

<a href="https://www.youtube.com/watch?v=aLI1V4kKFME" title="https://www.youtube.com/watch?v=aLI1V4kKFME">https://www.youtube.com/watch?v=aLI1V4kKFME</a>

Fed Chair Powell Says It's A Time Of Real Change In Geopolitics, Trade, Immigration; Doesn't Change How We Do Monetary Policy; Our Focus Is Practical

After two months of relative stability, new data from CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) Auto Finance (CAF) shows a renewed uptick in loan delinquencies and net losses, raising concerns about credit quality across the <a href="https://www.benzinga.com/topic/auto-loans">used auto lender's portfolio</a>.
Wedbush analyst Scott Devitt reiterated CarMax <a href="https://www.benzinga.com/quote/KMX/analyst-ratings" target="_blank" rel="noreferrer noopener">with an Outperform</a> and $90 price target on Wednesday.
On Monday, CAF reported securitization trust data for May, Devitt noted.
The analyst noted that after two relatively encouraging months, the data resumed weaker trends that were observed earlier in the year.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45953388/carmax-faces-acute-shortage-problem-and-it-might-last-through-2025" target="_blank" rel="noreferrer noopener">CarMax Faces &#8216;Acute&#8217; Shortage Problem, And It Might Last Through 2025</a>
He noted that, broadly, results were less favorable on a sequential basis compared to April but also worsened year over year.
May's delinquency and loss rates accelerated more sharply than typical seasonal trends, with newer securitizations performing no better—and in some cases worse—than older vintages. 
Devitt warns that sustained weakness in credit performance could weigh on future loan loss provisions, particularly as the company leans deeper into lower-tier borrowers to maintain interest margins. The analyst noted that the data showed renewed deterioration, including a sharp jump in the combined delinquency and extension rate and an accelerated rate of increase in the cumulative net loss rate.
While newer securitization vintages benefit from tighter credit standards and should be performing better than older ones, Devitt noted that for the most recent prime securitization, the delinquency rate is already trending in line to higher than older vintages.
Devitt will continue to monitor the potential impact of sustained weaker trends on loan loss provisions. He also pointed to his near-term estimates, which already assume an increasing percentage of loan loss provisions as the company leans deeper into Tier 2 and Tier 3 credit to drive interest margins further.
Based on his calculations, the portfolio-level delinquency rate (excluding the new 2025-A non-prime for comparability) increased +36bps sequentially, worse than the historical seasonal average of +18bps. In contrast, the cumulative loss rate increased +8bps versus a +1bps historical seasonal average increase.
Devitt said that on a Y/Y basis, the portfolio-level delinquency rate increased by +16bps, trending less favorably versus the trailing three-month trend of -2bps. The analyst noted that the cumulative net loss rate increased by +52bps Y/Y, consistent with the trailing three-month trend of +48bps.
Recent supply/demand dynamics have promoted healthy gross profit margins for scaled retailers. While trends have mostly started to normalize following a pull-forward of demand early this year, the used auto market remains healthy, per his discussion with Jonathan Smoke, Chief Economist at Cox Automotive, last week.
Devitt noted that CarMax has been able to sustain robust sourcing methods and integrated credit capabilities, supporting healthy performance despite an uncertain macro backdrop and a range of potential outcomes this year. Additionally, CarMax trends have outperformed recent reports of used car comps by publicly traded franchised dealers.
Devitt projected first-quarter revenue of $7.67 billion and earnings per share of $1.23.
Price Action: KMX stock is down 0.03% at $64.41 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45967870/stmicro-unveils-smart-sensor-to-cut-pc-power-use-boost-privacy" target="_blank" rel="noreferrer noopener">STMicro Unveils Smart Sensor To Cut PC Power Use, Boost Privacy</a></li>
</ul>
Image: Shutterstock

Price Target

Reiteration

CarMax Loan Delinquencies Tick Higher In May, Signaling Renewed Credit Strain

Fed Chair Powell Says Of Course Fed Is Watching Israel-Iran Conflict, Possible Will See Higher Energy Prices, But Don't Generally Tend To Have Lasting Effects On Inflation

Press Releases

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Life Sciences Investor Forum: Now Available for Online Viewing

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

ADIA

AMZN

ATNM

BPTH

CNVIF

COCH

COST

CSLLY

HSDT

INEO

KBSX

KZIA

MTVA

NIKA

PNPNF

PRSO

PYNKF

SDZNY

SNYR

SPHRY

STSS

TIVC

TRNR

TSXV:CNVI

TSXV:PINK

TSXV:PNPN

VYCO

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Elevation Oncology

Ernexa Therapeutics

FibroGen

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

HOOKIPA Pharma

Longeveron

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lisata Therapeutics

Marker Therapeutics

Nanoviricides

Ovid Therapeutics

Passage Bio

Q32 Bio

SAB Biotherapeutics

Tenax Therapeutics

HC Wainwright & Co.

EF Hutton

Alliance Global Partners

WIIM

IMUNON shares are trading lower. The company announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001.

Comments

Imunon

Noticias

Últimas noticias sobre Imunon (NASDAQ:IMNN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL